Literature DB >> 9342683

Paced Auditory Serial Addition Test: adult norms and moderator variables.

A N Wiens1, K H Fuller, J R Crossen.   

Abstract

This study examined the performance of a sample of 821 healthy job applicants on the Paced Auditory Serial Addition Test (PASAT). Subjects had previously passed basic academic skills tests and physical examinations and were deemed free of cognitive impairment and medical illness. They were also motivated to perform well on cognitive tests. Gender, ethnicity, and education were not significant moderator variables in our subjects. Age and IQ did significantly affect PASAT test results. Normative data are stratified by age and WAIS-R Full Scale IQ scores to be useful to those who administer the PASAT in clinical practice.

Entities:  

Mesh:

Year:  1997        PMID: 9342683     DOI: 10.1080/01688639708403737

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  17 in total

1.  Augmenting cognitive training in older adults (The ACT Study): Design and Methods of a Phase III tDCS and cognitive training trial.

Authors:  Adam J Woods; Ronald Cohen; Michael Marsiske; Gene E Alexander; Sara J Czaja; Samuel Wu
Journal:  Contemp Clin Trials       Date:  2017-12-05       Impact factor: 2.226

2.  Does the scoring of late responses affect the outcome of the paced auditory serial addition task (PASAT)?

Authors:  Julie Balzano; Nancy Chiaravalloti; Jeannie Lengenfelder; Nancy Moore; John DeLuca
Journal:  Arch Clin Neuropsychol       Date:  2006-10-25       Impact factor: 2.813

3.  Factors related to HIV-associated neurocognitive impairment differ with age.

Authors:  Gary B Fogel; Susanna L Lamers; Andrew J Levine; Miguel Valdes-Sueiras; Michael S McGrath; Paul Shapshak; Elyse J Singer
Journal:  J Neurovirol       Date:  2014-11-18       Impact factor: 2.643

4.  Functional polymorphisms in dopamine-related genes: effect on neurocognitive functioning in HIV+ adults.

Authors:  Andrew J Levine; Janet S Sinsheimer; Robert Bilder; Paul Shapshak; Elyse J Singer
Journal:  J Clin Exp Neuropsychol       Date:  2011-11-14       Impact factor: 2.475

5.  The Brief Repeatable Battery: psychometrics and normative values with age, education and gender corrections in a Serbian population.

Authors:  D Obradovic; M Petrovic; I Antanasijevic; J Marinkovic; T Stojanovic; S Obradovic
Journal:  Neurol Sci       Date:  2012-05-03       Impact factor: 3.307

6.  Long-term cognitive dysfunction after radiation therapy for primary brain tumors.

Authors:  Lene Haldbo-Classen; Ali Amidi; Lisa M Wu; Slavka Lukacova; Gorm von Oettingen; Hanne Gottrup; Robert Zachariae; Morten Høyer
Journal:  Acta Oncol       Date:  2019-02-13       Impact factor: 4.089

7.  Heart rate variability and intima media thickness.

Authors:  Nanna Hurwitz Eller; Birgitta Malmberg; Peter Bruhn
Journal:  Int J Behav Med       Date:  2006

8.  Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: the modulating effects of older age and disease severity.

Authors:  Stella E Panos; Charles H Hinkin; Elyse J Singer; April D Thames; Sapna M Patel; Janet S Sinsheimer; A C Del Re; Benjamin B Gelman; Susan Morgello; David J Moore; Andrew J Levine
Journal:  Neurobehav HIV Med       Date:  2013-06-19

Review 9.  Update on the Clinical, Radiographic, and Neurobehavioral Manifestations in FXTAS and FMR1 Premutation Carriers.

Authors:  Deborah A Hall; Erin Robertson; Annie L Shelton; Molly C Losh; Montserrat Mila; Esther Granell Moreno; Beatriz Gomez-Anson; Verónica Martínez-Cerdeño; Jim Grigsby; Reymundo Lozano; Randi Hagerman; Lorena Santa Maria; Elizabeth Berry-Kravis; Joan A O'Keefe
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

10.  A comparison of screening batteries in the detection of neurocognitive impairment in HIV-infected Spanish speakers.

Authors:  Andrew J Levine; Manuel Palomo; Charles H Hinkin; Miguel Valdes-Sueiras; Enrique Lopez; Glenn Mathisen; Suzanne Donovan; Elyse J Singer
Journal:  Neurobehav HIV Med       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.